Group 1 - The company has decided to cancel its supervisory board, transferring its responsibilities to the audit committee of the board of directors [2][4][56] - The decision to cancel the supervisory board and amend the company's articles of association and related rules requires approval from the shareholders' meeting [4][56] - The company has appointed Tianjian Accounting Firm as its auditor for the 2025 fiscal year, with an audit fee of 780,000 RMB [6][15][64] Group 2 - The company held its eighth board meeting on August 29, 2025, where it approved several resolutions, including the cancellation of the supervisory board and the appointment of the accounting firm [41][46][56] - The company plans to hold a half-year performance briefing on September 30, 2025, to discuss its operating results and financial status for the first half of 2025 [33][35][36]

Group 1 - The company Jiarun Technology announced the convening of its fourth board meeting on August 26, 2025, in Chengdu, where it reviewed the proposal for establishing a "Market Value Management System" [1] - The meeting was conducted in a hybrid format, combining in-person attendance and remote voting [1] Group 2 - The news highlights a significant advancement in medical technology with the world's first successful transplantation of gene-edited pig lungs into a human [1] - The article includes a dialogue with key participants discussing the timeline and challenges for clinical application of this breakthrough [1]

Group 1 - The company held its 13th meeting of the 5th Board of Directors on May 13, 2025, where all 5 directors attended, and the meeting was deemed legally valid [2][4] - The Board approved the proposal to use up to RMB 55 million of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months from the date of approval [3][15][18] Group 2 - The Supervisory Board also convened on May 13, 2025, with all 3 supervisors present, and the meeting was legally valid [10][11] - The Supervisory Board approved the same proposal regarding the use of idle raised funds, confirming that the decision followed necessary procedures and complied with relevant regulations [11][19] Group 3 - The company previously used idle raised funds for working capital in May 2024 and July 2024, with all funds returned to the designated account before the due date [17][18] - The company aims to improve the efficiency of fund usage and reduce financial costs while ensuring that the investment projects funded by the raised capital remain unaffected [16][18]

Core Viewpoint - The supervisory board of Hualan Biological Engineering Co., Ltd. held its 15th meeting of the 8th session, approving several key proposals including the annual report, profit distribution plan, and changes in accounting policies, all of which will be submitted for shareholder approval at the upcoming annual general meeting [1][2][3]. Meeting Overview - The meeting was held on March 28, 2025, with all three supervisory board members present, complying with legal and regulatory requirements [1]. Resolutions Passed - The supervisory board approved the 2024 Annual Work Report, which will be submitted for shareholder review [2]. - The 2024 Annual Report and its summary were also approved, confirming that the report accurately reflects the company's situation without any misleading statements [2]. - The 2024 Financial Settlement Report was approved, pending shareholder approval [2]. - A profit distribution plan was approved, proposing a cash dividend of 2 yuan per 10 shares, totaling approximately 365.76 million yuan, with remaining undistributed profits rolling over to the next year [2][3]. - Changes to accounting policies and estimates were approved, ensuring compliance with the latest accounting standards without significantly impacting the company's financial status [3][4]. - The 2024 Internal Control Self-Evaluation Report was approved, indicating a robust internal control system in place [4]. - The proposal to use idle funds for investment and financial management was approved, aimed at improving fund utilization efficiency [5]. - The reappointment of the auditing firm for 2025 was approved, pending shareholder approval [5]. - The proposal to repurchase and cancel certain restricted stock options from the 2023 incentive plan was approved, ensuring compliance with relevant regulations [6]. - A proposal to amend the company's registered capital and related articles in the Articles of Association was approved, pending shareholder approval [6][7]. - The establishment of a Public Opinion Management System and a Market Value Management System was approved [7].